All projects are different, but a number of parameters are consistent in addition to the guidelines/requirements from ICH, FDA, EMA. Selected characteristics of Small Molecule development projects will be discussed.
Highlighting topics concerning:
- Management of risk and investment
- Optimization and adaptation of MedChem procedures towards manufacturing
- Sustainability
- Introduction of green(-er) chemistry
- Cost of waste management
- Selection and sourcing of raw materials
- Risk balancing of time versus cost
- Delivery stages, hard and soft deadlines
- Staging of the overall development-costs
When should each activity be initiated?
How to manage this?
Date: Wednesday 17th of January 2024
Time: 8:30 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Meeting room: Auditorium
Program
08:30 | Networking, registration, and light breakfast |
09:00 | Welcome David Munis Zepernick, Director, Member Engagement & Communication, Medicon Valley Alliance |
09:05 | Company Introduction, Raybow Peter Halkjær-Knudsen, CEO of Raybow Europe, Head of Mergers and Acquisitions, Jiuzhou Pharmaceuticals |
09:20 | Selection of CDMO for your Project – When, Who and How? How to secure a smooth and efficient transfer of a small molecule from Research to Market Peter Halkjær-Knudsen, CEO of Raybow Europe, Head of Mergers and Acquisitions, Jiuzhou Pharmaceuticals |
10:00 | Q&A session |
10:15 | Networking |
11:00 | End of Good Morning Meeting |
Speaker
Organized by | In collaboration with |
![]() |
![]() |